Sophiris Bio (SPHS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2019 | 06-2019 | 03-2019 | 12-2018 | 09-2018 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -5,483 | -4,524 | -2,360 | -6,778 | -12,298 |
| Depreciation Amortization | 206 | 142 | 71 | 156 | 114 |
| Accounts payable and accrued liabilities | -1,459 | -1,241 | -1,002 | 963 | -433 |
| Other Working Capital | -2,008 | -947 | -807 | 987 | 309 |
| Other Operating Activity | 317 | 834 | 674 | -8,785 | 967 |
| Operating Cash Flow | $-8,427 | $-5,736 | $-3,424 | $-13,457 | $-11,341 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | N/A | -4 | -4 |
| Purchase Of Investment | -3,082 | -1,038 | -444 | -3,616 | -2,081 |
| Sale Of Investment | 2,600 | 1,550 | 650 | 11,887 | 9,387 |
| Investing Cash Flow | $-482 | $512 | $206 | $8,267 | $7,302 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -1,400 | -700 | N/A | N/A | N/A |
| Common Stock Issued | 3,664 | N/A | N/A | 102 | N/A |
| Other Financing Activity | -102 | -102 | -102 | 0 | 0 |
| Financing Cash Flow | $2,162 | $-802 | $-102 | $102 | $N/A |
| Exchange Rate Effect | N/A | N/A | N/A | -1 | N/A |
| Beginning Cash Position | 10,998 | 10,998 | 10,998 | 16,087 | 16,087 |
| End Cash Position | 4,251 | 4,972 | 7,678 | 10,998 | 12,048 |
| Net Cash Flow | $-6,747 | $-6,026 | $-3,320 | $-5,089 | $-4,039 |
| Free Cash Flow | |||||
| Operating Cash Flow | -8,427 | -5,736 | -3,424 | -13,457 | -11,341 |
| Capital Expenditure | N/A | N/A | N/A | -4 | -4 |
| Free Cash Flow | -8,427 | -5,736 | -3,424 | -13,461 | -11,345 |